Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Calculi Dissolution Agent [EPC]
Saccharomyces Cerevisiae Rna is a complex biological agent primarily classified as a Calculi Dissolution Agent, utilized for its acidifying and calcium-chelating properties in metabolic and renal health.
Name
Saccharomyces Cerevisiae Rna
Raw Name
SACCHAROMYCES CEREVISIAE RNA
Category
Calculi Dissolution Agent [EPC]
Drug Count
25
Variant Count
25
Last Verified
February 17, 2026
About Saccharomyces Cerevisiae Rna
Saccharomyces Cerevisiae Rna is a complex biological agent primarily classified as a Calculi Dissolution Agent, utilized for its acidifying and calcium-chelating properties in metabolic and renal health.
Detailed information about Saccharomyces Cerevisiae Rna
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Saccharomyces Cerevisiae Rna.
Saccharomyces Cerevisiae Rna (Ribonucleic Acid) is a biological substance derived from the cellular components of Saccharomyces cerevisiae, commonly known as baker's yeast or brewer's yeast. In a clinical and pharmacological context, this active ingredient is classified primarily as a Calculi Dissolution Agent [EPC]. This classification indicates its therapeutic utility in the management and dissolution of mineral deposits, such as renal calculi (kidney stones) or biliary stones. Beyond its primary role, Saccharomyces Cerevisiae Rna is associated with an unusually broad spectrum of Pharmacologic Class (EPC) designations, including Anti-coagulant, Adrenocorticotropic Hormone, alpha-Adrenergic Agonist, beta-Adrenergic Agonist, Catecholamine, and various nutritional categories such as Vitamin C, Vitamin D, Vitamin B12, and Omega-3 Fatty Acids. This diversity reflects the complex nature of yeast-derived extracts, which contain a dense matrix of nucleotides, enzymes, and cofactors.
Saccharomyces Cerevisiae Rna belongs to a class of drugs and supplements known as nucleotide-based therapeutic agents. While nucleic acids are fundamental components of all living cells, when administered in concentrated, standardized forms, they exert specific metabolic and physiological effects. Historically, yeast extracts have been used in clinical nutrition and immunology for decades. The FDA recognizes various yeast derivatives under different regulatory frameworks, often as Generally Recognized as Safe (GRAS) for nutritional purposes, though specific standardized extracts used for calculi dissolution are subject to more rigorous clinical oversight.
The mechanism of action (MoA) for Saccharomyces Cerevisiae Rna is multi-faceted, reflecting its complex chemical composition. At the molecular level, its primary therapeutic effect is driven by Acidifying Activity [MoA] and Calcium Chelating Activity [MoA].
The pharmacokinetics of Saccharomyces Cerevisiae Rna differ significantly from traditional small-molecule drugs due to its biological nature.
Saccharomyces Cerevisiae Rna is utilized for several clinical indications, both approved and investigated:
Saccharomyces Cerevisiae Rna is available in several formulations to accommodate different clinical needs:
> Important: Only your healthcare provider can determine if Saccharomyces Cerevisiae Rna is right for your specific condition. The complexity of its EPC classes requires a thorough medical evaluation to ensure safety and efficacy.
Dosage for Saccharomyces Cerevisiae Rna must be highly individualized based on the specific indication and the patient's metabolic profile.
Saccharomyces Cerevisiae Rna is not routinely recommended for pediatric use unless specifically directed by a pediatric nephrologist or metabolic specialist.
Patients with impaired kidney function require significant dosage adjustments. Since the metabolites of RNA (specifically purines) are cleared renally and can increase uric acid levels, patients with a GFR (Glomerular Filtration Rate) below 60 mL/min should start at the lowest possible dose. In cases of severe renal failure (GFR < 30 mL/min), the use of Saccharomyces Cerevisiae Rna may be contraindicated due to the risk of hyperuricemia and secondary gout.
No specific dosage adjustments are typically required for mild to moderate hepatic impairment, as the primary metabolism occurs via ubiquitous cellular enzymes. However, in cases of severe liver cirrhosis, monitoring of ammonia levels may be necessary due to the nitrogenous nature of RNA metabolites.
Geriatric patients should be started on the lower end of the dosing spectrum. Clinical consideration must be given to the increased prevalence of reduced renal function and the potential for polypharmacy interactions in this population.
If a dose is missed, it should be taken as soon as the patient remembers. If it is nearly time for the next scheduled dose, the missed dose should be skipped. Do not double the dose to make up for a missed one, as this increases the risk of metabolic imbalances.
Signs of acute overdose may include severe nausea, vomiting, abdominal cramping, and joint pain (indicative of acute gouty arthritis). In severe cases, it may lead to metabolic acidosis or acute renal uric acid nephropathy.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as this may lead to a recurrence of stone formation.
Most patients tolerate Saccharomyces Cerevisiae Rna well, but some may experience mild gastrointestinal or metabolic effects. Common side effects include:
> Warning: Stop taking Saccharomyces Cerevisiae Rna and call your doctor immediately if you experience any of these serious symptoms:
Prolonged use of Saccharomyces Cerevisiae Rna requires monitoring for:
At present, there are no FDA black box warnings specifically for Saccharomyces Cerevisiae Rna. However, it is important to note that many products containing this ingredient are marketed as dietary supplements or non-standardized extracts, which may not have undergone the same rigorous safety labeling as synthetic pharmaceuticals.
Report any unusual symptoms or changes in your health to your healthcare provider promptly. Regular blood work is recommended for those on long-term therapy to monitor uric acid and renal function.
Saccharomyces Cerevisiae Rna is a biologically active substance that can significantly alter metabolic processes, particularly those involving purine metabolism and urinary chemistry. Patients must be aware that while it is derived from a common food source (yeast), in concentrated therapeutic doses, it acts as a drug. It is not a substitute for standard medical care in the management of acute kidney stones or severe metabolic disorders.
No FDA black box warnings for Saccharomyces Cerevisiae Rna.
Your healthcare provider will likely require periodic laboratory testing to ensure the medication is working safely:
Saccharomyces Cerevisiae Rna generally does not cause drowsiness or cognitive impairment. However, if you experience headaches or dizziness during the initial phase of treatment, avoid driving or operating heavy machinery until you know how the medication affects you.
Alcohol consumption should be strictly limited while taking this medication. Alcohol, particularly beer (which also contains yeast and purines), can significantly increase uric acid levels and decrease the renal excretion of urate, greatly increasing the risk of a gout attack and reducing the efficacy of calculi dissolution.
There is no known withdrawal syndrome associated with Saccharomyces Cerevisiae Rna. However, stopping the medication abruptly may lead to a rebound increase in urinary pH, potentially accelerating the formation of new kidney stones in susceptible individuals. It is often best to taper the dose under medical supervision while increasing dietary fluid intake.
> Important: Discuss all your medical conditions, especially a history of gout, kidney disease, or yeast allergies, with your healthcare provider before starting Saccharomyces Cerevisiae Rna.
For each interaction, the mechanism typically involves either pharmacodynamic synergy (e.g., additive anticoagulant effects) or metabolic competition (e.g., purine processing). Management usually involves dose timing adjustments or increased clinical monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter vitamins.
Saccharomyces Cerevisiae Rna must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a healthcare provider:
Patients who are allergic to other fungi, such as Candida albicans, or those who have reactions to mold-ripened cheeses, may exhibit cross-sensitivity to Saccharomyces Cerevisiae Rna. Caution is advised when initiating therapy in any patient with a broad profile of environmental or food allergies.
> Important: Your healthcare provider will evaluate your complete medical history, including all allergies and metabolic conditions, before prescribing Saccharomyces Cerevisiae Rna.
FDA Pregnancy Category: Not Formally Assigned (Typically treated as Category C).
There are no adequate and well-controlled studies of Saccharomyces Cerevisiae Rna in pregnant women. Animal reproduction studies have not been conducted. It is unknown whether the increased purine load or the adrenergic activity of the drug could affect fetal development or uterine tone. Use during pregnancy is generally not recommended unless a physician determines that the benefits to the mother significantly outweigh the risks to the fetus. Specifically, avoid use in the first trimester when organogenesis is occurring.
It is unknown whether the specific nucleotide fragments or metabolites of Saccharomyces Cerevisiae Rna are excreted in human milk. While yeast is a common dietary component, the therapeutic concentrations used in this medication are much higher. There is a theoretical risk that increased uric acid levels in milk could affect the infant's developing renal system. Breastfeeding women should consult their doctor; in many cases, it is advised to either discontinue the drug or cease breastfeeding.
Safety and effectiveness in pediatric patients have not been established. The use of a Calculi Dissolution Agent in children is a highly specialized area of medicine. There are concerns that long-term use could affect growth due to the drug's influence on calcium metabolism and its EPC classification involving Adrenocorticotropic Hormone and various vitamins. If used, it must be under the strict guidance of a pediatric specialist.
Clinical studies have not included sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, because elderly patients are more likely to have decreased renal function and are often taking multiple medications (polypharmacy), they are at a higher risk for side effects like hyperuricemia and drug interactions. Monitoring of renal function and uric acid is mandatory in this population. The risk of falls may be slightly increased if the drug causes dizziness or interacts with antihypertensive medications.
In patients with mild to moderate renal impairment (GFR 30-60 mL/min), the clearance of uric acid is reduced. This necessitates a lower starting dose and more frequent monitoring. Saccharomyces Cerevisiae Rna is generally avoided in patients with a GFR < 30 mL/min due to the high risk of metabolic complications and the potential for the drug to worsen renal function through the precipitation of urate crystals.
No specific dose adjustments are provided for patients with hepatic impairment. However, since the liver is a major site for nucleotide metabolism, patients with severe liver disease (Child-Pugh Class C) should be monitored for signs of nitrogenous waste accumulation.
> Important: Special populations require an individualized medical assessment and frequent clinical follow-up to ensure safety.
Saccharomyces Cerevisiae Rna functions as a complex biological modifier. Its primary action as a Calculi Dissolution Agent is mediated through the metabolic generation of acidic residues which lower urinary pH, thereby increasing the solubility of calcium-based stones. Simultaneously, the nucleotide fragments act as Calcium Chelators, binding to free calcium ions in the urine and preventing them from reacting with oxalate or phosphate to form insoluble crystals.
On a cellular level, the RNA fragments may interact with Purinergic Receptors (P2X and P2Y). These receptors are involved in a wide array of physiological processes, including the modulation of vascular tone and immune response, which accounts for the drug's EPC classification as an alpha and beta-adrenergic agonist. By influencing these receptors, the drug can affect the smooth muscle of the ureters, potentially aiding in the passage of stone fragments.
The pharmacodynamic effect on urinary pH is typically observed within 24 to 48 hours of starting therapy. The duration of the effect lasts as long as the medication is consistently administered. Tolerance to the acidifying effect is rare, though the body may compensate over time by increasing renal ammonia production. There is no evidence of psychological dependence, but physiological reliance on the drug for stone prevention is common in chronic stone-formers.
| Parameter | Value |
|---|---|
| Bioavailability | 70-90% (as nucleotide fragments) |
| Protein Binding | Minimal (<10%) |
| Half-life | 1.5 - 4 hours (metabolites) |
| Tmax | 1 - 2 hours |
| Metabolism | Intestinal hydrolysis; Hepatic/Cellular purine pathway |
| Excretion | Renal (85%), Fecal (15%) |
Saccharomyces Cerevisiae Rna is classified as a Calculi Dissolution Agent [EPC]. It is related to other urinary acidifiers like ammonium chloride, but differs due to its biological origin and additional chelating and adrenergic properties. It is often found in the company of other yeast-derived products used in immunology and clinical nutrition.
Medications containing this ingredient
Common questions about Saccharomyces Cerevisiae Rna
Saccharomyces Cerevisiae Rna is primarily used as a Calculi Dissolution Agent to help dissolve and prevent kidney stones, particularly those made of calcium. It works by acidifying the urine and chelating (binding) calcium to keep it from forming solid crystals. Additionally, because it is derived from yeast, it provides a source of B vitamins and amino acids, making it useful for nutritional support. Some healthcare providers also use it in specialized immune-related treatments or allergenic extracts. It is important to note that it should only be used under medical supervision to ensure it is appropriate for your specific type of kidney stone.
The most common side effects include gastrointestinal issues such as nausea, bloating, gas, and mild diarrhea, which often occur as the body adjusts to the yeast-derived material. Some patients also report an increased frequency of urination and mild headaches. Because the RNA breaks down into uric acid, a significant number of patients may experience an increase in blood uric acid levels. In some cases, this can lead to joint pain or even a gout attack in susceptible individuals. Most mild side effects resolve on their own, but persistent symptoms should be reported to a doctor.
It is strongly advised to avoid or strictly limit alcohol consumption while taking Saccharomyces Cerevisiae Rna. Alcohol, especially beer, is high in purines and can interfere with the body's ability to clear uric acid, which is the main byproduct of this medication. Combining the two significantly increases your risk of developing gout or uric acid-based kidney stones. Furthermore, alcohol can change your urine pH and hydration levels, potentially making the medication less effective at dissolving calcium stones. Always discuss your lifestyle habits with your healthcare provider when starting this treatment.
The safety of Saccharomyces Cerevisiae Rna during pregnancy has not been clearly established through clinical trials. It is generally classified as a drug that should only be used if the potential benefits to the mother outweigh the potential risks to the developing fetus. There are concerns that the metabolic changes it causes, such as increased uric acid or altered adrenergic activity, could impact the pregnancy. If you are pregnant or planning to become pregnant, you must consult your doctor before using this medication. Most physicians will recommend alternative treatments for kidney stones during pregnancy unless the situation is critical.
The chemical effects of Saccharomyces Cerevisiae Rna, such as the acidification of the urine, typically begin within 24 to 48 hours of the first few doses. However, the actual dissolution of an existing kidney stone is a much slower process that can take weeks or even months of consistent use. For the prevention of new stones, the medication must be taken long-term to maintain the proper urinary environment. Patients are usually monitored with follow-up imaging, such as ultrasounds or CT scans, every 3 to 6 months to evaluate the progress of stone dissolution. Consistency in dosing and high fluid intake are key to its success.
While you can technically stop taking Saccharomyces Cerevisiae Rna without experiencing withdrawal symptoms like those seen with narcotics or antidepressants, it is not recommended to do so without consulting your doctor. Stopping the medication suddenly can cause your urinary pH to return to its previous levels, which may lead to a rapid recurrence or growth of kidney stones. If you need to stop the medication, your doctor may suggest a tapering schedule or recommend dietary changes and increased water intake to compensate for the loss of the drug's stone-preventing effects. Always finish the prescribed course unless directed otherwise.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at once to make up for the one you missed, as this can lead to an upset stomach or a temporary spike in uric acid levels. Maintaining a steady level of the medication in your system is important for effective stone management, so try to use a pillbox or phone reminder to stay on track. If you miss several doses in a row, contact your healthcare provider for advice.
There is no significant clinical evidence to suggest that Saccharomyces Cerevisiae Rna causes weight gain. It is not a high-calorie supplement, and its primary actions are metabolic and renal rather than hormonal or appetite-stimulating. However, some patients may experience mild bloating or water retention during the first few days of therapy, which could be mistaken for weight gain. If you notice a sudden or significant increase in weight, it is more likely related to other factors, such as changes in diet, activity levels, or other medications, and you should discuss it with your doctor to rule out any underlying issues.
Saccharomyces Cerevisiae Rna can interact with several types of medications, so a full review of your current prescriptions is necessary. It may interact with blood thinners like warfarin, blood pressure medications, and drugs used to treat gout, such as allopurinol. Because it has adrenergic activity, it can also interact with decongestants or asthma medications. Furthermore, taking it with other vitamin supplements might lead to excessive intake of certain nutrients like Vitamin D or B12. Always provide your healthcare provider with a complete list of all medications, herbs, and supplements you are currently taking.
Saccharomyces Cerevisiae Rna is often available as a generic ingredient, frequently found in various nutritional supplements, homeopathic remedies, and specialized medical foods. Because it is a biological extract, different brands may have slightly different concentrations or standardized levels of RNA. It is important to use a high-quality, standardized product if you are using it for a specific medical condition like kidney stones. Your doctor or pharmacist can help you select a reputable version of the medication that meets the necessary clinical standards for your treatment plan.